Cardiovascular (CV)-Related Hospitalizations and Associated Costs Among US Patients in Simplicity: An Observational Study of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in Routine Clinical Practice

被引：0
|
作者：
Goldberg, Stuart L. [1 ]
Mauro, Michael J. [2 ]
Cortes, Jorge E. [3 ]
Keating, Scott Justin [4 ]
Bhandari, Hitesh [5 ]
Chen, Clara [4 ]
机构：
[1] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA
[2] Mem Sloan Kettering Canc Ctr, Myeloproliferat Neoplasms Program, Leukemia Serv, 1275 York Ave, New York, NY 10021 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[4] Bristol Myers Squibb, Princeton, NJ USA
[5] SmartAnalyst India Pvt Ltd, Gurgaon, India
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-128290
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4151
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Treatment Patterns in Patients with Chronic-Phase Chronic Myeloid Leukaemia in Routine Clinical Practice: the SIMPLICITY Italian Population
    Abruzzese, Elisabetta
    Bosi, Alberto
    Breccia, Massimo
    D'Adda, Mariella
    Di Renzo, Nicola
    Liberati, Anna Marina
    Porrini, Raffaele
    Orlandi, Ester Maria
    Pane, Fabrizio
    Pungolino, Ester
    Sora, Federica
    Stagno, Fabio
    Sen, Ginny P.
    Gentilini, Fabiana
    De Solda, Francesco
    Gambacorti-Passerini, Carlo
    MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2019, 11
  • [22] Correction: Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials
    Jabbour, Elias
    Apperley, Jane
    Cortes, Jorge
    Rea, Delphine
    Deininger, Michael
    Abruzzese, Elisabetta
    Chuah, Charles
    Deangelo, Daniel J.
    Hochhaus, Andreas
    Lipton, Jeffrey H.
    Mauro, Michael
    Nicolini, Franck
    Pinilla-Ibarz, Javier
    Rosti, Gianantonio
    Rousselot, Philippe
    Shah, Neil P.
    Talpaz, Moshe
    Vorog, Alexander
    Ren, Xiaowei
    Kantarjian, Hagop
    LEUKEMIA, 2024, 38 (10) : 2291 - 2291
  • [23] Early Optimization of Imatinib Therapy in Patients Newly Diagnosed with Chronic-Phase Chronic Myeloid Leukemia (CP-CML). A Study of the Spanish PETHEMA Group.
    Cervantes, Francisco
    Lopez-Garrido, Pilar
    Montero, Maria-Isabel
    Jonte, Femin
    Martinez, Jesus
    Hernan-dez-Boluda, Juan-Carlos
    Calbacho, Maria
    Sureda, Anna
    Perez-Rus, Gloria
    Nieto, Jose
    Perez-Lopez, Cristina
    Roman, Jose
    Gonzalez, Marcos
    Pereira, Arturo
    Colomer, Dolors
    BLOOD, 2009, 114 (22) : 456 - 457
  • [24] COMPARISON OF PACE CLINICAL TRIAL VS REAL-WORLD PONATINIB PRESCRIBING AND DURATION OF THERAPY IN CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) PATIENTS
    Mauro, M.
    McGarry, L. J.
    Yang, M.
    Lustgarten, S.
    Huang, H.
    HAEMATOLOGICA, 2016, 101 : 458 - 458
  • [25] MINIMUM FOLLOW-UP OF 4 YEARS FOR ONGOING PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) IN A PHASE 1 TRIAL OF PONATINIB
    Talpaz, M.
    Cortes, J. E.
    Kantarjian, H. M.
    Shah, N. P.
    Bixby, D. L.
    Flinn, I. W.
    O'Hare, T. J.
    Hu, S.
    Rivera, V. M.
    Clackson, T.
    Conlan, M. G.
    Haluska, F. G.
    Druker, B. J.
    Deininger, M. W.
    Mauro, M. J.
    HAEMATOLOGICA, 2015, 100 : 65 - 66
  • [26] An Observational Study of Survival in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) After 1, 3, and 5 Years of Tyrosine Kinase Inhibitor (TKI) Therapy (SIMPLICITY)
    Michallet, Mauricette
    Cortes, Jorge
    Gambacorti-Passerini, Carlo
    Hehlmann, Rudiger
    Williams, Loretta A.
    Goldberg, Stuart L.
    Davis, Catherine
    De Solda, Francesco
    Sen, Ginny P.
    Gajavelli, Srikanth
    Mauro, Michael J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S229 - S229
  • [27] Resistance to imatinib among patients in chronic phase (CP) of chronic myelogenous leukemia (CML) in clinical practice
    Davis, C.
    Sanders, L.
    Hirji, I.
    Oliveria, S.
    Willey, V. J.
    Phillips, S.
    Yood, M. Ulcickas
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [28] Resistance, Outcome and the Development of Mutations with Dasatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP).
    Shah, Neil
    Bahceci, Erkut
    Lambert, Alexandre
    Ploughman, Lynn
    Radich, Jerald
    BLOOD, 2009, 114 (22) : 460 - 460
  • [29] Survival Outcomes in Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Receiving Third- or Subsequent Line (3L) Treatment
    Stellato, Daniel R.
    McGarry, Lisa
    Huang, Hui
    Hastings, Shaina
    Delea, Thomas E.
    Lipton, Jeffrey H.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S311 - S312
  • [30] Is Quality of Life (QOL) Predictive for Clinical Response in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients Treated with Dasatinib?
    Ionova, Tatiana
    Bulieva, Natalia
    Golenkov, Anatoly
    Gritsenko, Taras
    Kozlova, Lilia
    Kuchma, Galina
    Lomaia, Elza
    Machulaytene, Elena
    Nikitina, Tatiana
    Novitskaya, Natalia
    Usacheva, Elena
    Shneider, Tatiana
    Trifonova, Elena
    Vinogradova, Olga
    Zinkovskaya, Anna
    BLOOD, 2017, 130
12345